Medicare has proposed not to pay for tests to determine the proper dose of wafarin for a patient due to insufficient evidence of their effectiveness compared to current methods. The genetic tests costs $50–$500. However, Medicare stated it would pay for the tests in clinical trials. The public may comment on the proposal for one month.

Source: New York Times